Vδ2 γδT cells present allogeneic potential,[29] and tumor‐infiltrating Vδ2 γδT cells are associated with favorable outcomes in multiple cancer types.[51] The particular antigen‐presenting capacity of Vδ2 γδT may provide therapeutic benefits through stimulating adaptive immunity.[25, 26] On the other hand, the intrinsic anticancer activity of Vδ2 γδT is independent of CAR and MHC,[27] which may complement our CAR.BiTE system against tumor cells with insufficient antigens. The gene discussed is HLA-C; the disease is neoplasm.